Study Title: NIV001
NIV001: A phase I safety and immunogenicity trial of a Nipah virus vaccine, ChAdOx1 NipahB, in healthy volunteers aged 18-55 years in the UK
You are invited to take part in a study to investigate a new vaccine against Nipah – a viral illness which causes outbreaks. The World Health Organization recognises Nipah as a priority disease to develop vaccines because there are currently none available. The trial vaccine has been developed by the University of Oxford. The study is taking place at the Centre for Clinical Vaccinology and Tropical Medicine at the Churchill Hospital.
If you are aged 18 to 55 years old, in good health and live in the Thames Valley area, then you may be eligible to take part. We will provide reimbursement of £1,020 - £1,380 for your time, inconvenience and travel. The total study participation time is 12 months.
If you would like to find out more, please read the Participant Information Sheet and if you are interested in joining the study, please visit where you can access the screening questions and register your interest Pre-screening .
If you would like any further information regarding the study, please contact us on:
Email info@ovg.ox.ac.uk, Tel: 01865 611400
Kind Regards,
The Oxford Vaccine Group